CN Patent

CN112094272A — Cdk激酶抑制剂

Assigned to Beijing Ruixi Biotechnology Co ltd · Expires 2020-12-18 · 5y expired

What this patent protects

本申请公开了一种可作为CDK激酶(尤其是CDK4/6激酶)抑制剂的通式(I)化合物及其盐，其中所有变量如本文所定义。该化合物可用于治疗或预防癌症等疾病。本申请还涉及包含式(I)化合物的药用组合物。

USPTO Abstract

本申请公开了一种可作为CDK激酶(尤其是CDK4/6激酶)抑制剂的通式(I)化合物及其盐，其中所有变量如本文所定义。该化合物可用于治疗或预防癌症等疾病。本申请还涉及包含式(I)化合物的药用组合物。

Drugs covered by this patent

ribociclib-succinate (RIBOCICLIB SUCCINATE)

Patent Metadata

Patent number: CN112094272A
Jurisdiction: CN
Classification: —
Expires: 2020-12-18
Drug substance claim: No
Drug product claim: No
Assignee: Beijing Ruixi Biotechnology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.